Cargando…

AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?

Epidermal growth factor receptor (EGFR) is highly expressed in triple-negative breast cancer (TNBC), and elevated levels correlate with poor prognosis. In analogy with the paradigm of oncogene addiction, blocking EGFR in TNBC was expected to have clinical efficacy – but this has not been the case. R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heideman, Marinus R, Hynes, Nancy E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978757/ https://www.ncbi.nlm.nih.gov/pubmed/24172042 http://dx.doi.org/10.1186/bcr3564

Ejemplares similares

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC
por: Ghiso, Elena, et al.
Publicado: (2017)

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
por: Magkou, Christina, et al.
Publicado: (2008)

ADAM metalloproteases and EGFR signalling
por: Gee, Julia MW, et al.
Publicado: (2003)

Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation
por: Brown, Wells S, et al.
Publicado: (2014)

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
por: Nakamura, Ryota, et al.
Publicado: (2023)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
por: Vouri, M, et al.
Publicado: (2016)

Epidermal growth factor receptors (EGFR) in human ovarian cancer.
por: Owens, O. J., et al.
Publicado: (1991)

Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer
por: Berasain, Carmen, et al.
Publicado: (2011)

Nuclear localization of epidermal growth factor receptor (EGFR) in ameloblastomas
por: Pereira, Núbia Braga, et al.
Publicado: (2015)

Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
por: Zhang, Zhenfeng, et al.
Publicado: (2012)

Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)
por: Makhov, Petr, et al.
Publicado: (2021)

Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer
por: Hong, Chang‐Soo, et al.
Publicado: (2020)

FLOWER-MI and the root of the problem with non-culprit revascularisation
por: Li Kam Wa, Matthew E, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
por: Makinoshima, Hideki, et al.
Publicado: (2014)

Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma
por: Wernicke, A Gabriella, et al.
Publicado: (2010)

Targeting Epidermal Growth Factor Receptor (EGFR) in Pediatric Colorectal Cancer
por: De Pasquale, Maria Debora, et al.
Publicado: (2020)

Association of epidermal growth factor receptor (EGFR) gene polymorphisms with endometriosis
por: Wang, Yu-Mei, et al.
Publicado: (2019)

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
por: Russo, Alessandro, et al.
Publicado: (2019)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

Influence of Macrocyclization on Allosteric, Juxtamembrane-Derived, Stapled Peptide Inhibitors of the Epidermal Growth Factor Receptor (EGFR)
por: Sinclair, Julie K.-L., et al.
Publicado: (2014)

Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption: Three case reports
por: Fang, Szu-Yun, et al.
Publicado: (2019)

Preliminary Discovery of Small Molecule Inhibitors of Epidermal Growth Factor Receptor (EGFR) That Bind to the Extracellular Domain
por: Di Liddo, Rosa, et al.
Publicado: (2022)

Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer
por: Weng, Xiaoling, et al.
Publicado: (2015)

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
por: Sasada, Tetsuro, et al.
Publicado: (2016)

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
por: Abd El-Rehim, D M, et al.
Publicado: (2004)

Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
por: Cao, Wen-Ming, et al.
Publicado: (2015)

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
por: Choi, Yong Won, et al.
Publicado: (2017)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
por: Xie, Yalin, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
por: Peraldo-Neia, Caterina, et al.
Publicado: (2011)

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
por: Kaufman, Nichole E. M., et al.
Publicado: (2021)

Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2017)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
por: Chen, Yongshun, et al.
Publicado: (2016)

Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
por: Moriya, Tetsuji, et al.
Publicado: (2021)

CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Hara, Naofumi, et al.
Publicado: (2023)

Piperonylic acid stimulates keratinocyte growth and survival by activating epidermal growth factor receptor (EGFR)
por: Lee, Dohyun, et al.
Publicado: (2018)

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021)

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
por: Jorge, S.E.D.C., et al.
Publicado: (2014)

Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
por: Rayego-Mateos, Sandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4s145mu16ufq86bp17qd02j4uf